Circulating microRNAs in Dogs with Cushing's Syndrome for Biomarker Discovery

20 circulating microRNAs were analyzed in blood samples from 6 healthy dogs, 19 dogs with pituitary-dependent hypercortisolism, and 26 dogs with cortisol-secreting adrenocortical tumors. The study, conducted by Karin Sanders of Utrecht University, identified specific miRNAs differentially expressed between healthy and diseased dogs, including miR-122-5p which showed no overlap in expression levels between healthy dogs and those with PDH. Results indicate the potential of these miRNAs as noninvasive biomarkers to aid clinical decision-making for canine Cushing's syndrome.

Use Cases

• Identify potential noninvasive biomarkers for canine Cushing's syndrome based on circulating miRNA expression levels.
• Compare miRNA profiles between pituitary-dependent and adrenal tumor forms of the disease to understand pathological differences.
• Assess the correlation between specific miRNA expression (e.g., miR-141-3p) and histopathological tumor scores.
• Evaluate the prognostic value of miRNAs like miR-122-5p for predicting recurrence risk after surgery.

Strengths

• Analysis includes pre- and post-operative samples for 19 dogs with pituitary-dependent hypercortisolism.
• Definitive study analyzed 20 selected miRNAs across a total of 51 canine blood samples.
• Identified six miRNAs differentially expressed in PDH and two in csACTs compared to healthy controls with specific p-values reported.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• Sample sizes for the pilot study were small (3 healthy, 3 PDH, 4 csACT).
• Last update date is unknown; freshness unverified.

Provenance

Source

Karin Sanders, Utrecht University

Collection Method

Blood sample collection and miRNA analysis from dogs with Cushing's syndrome and healthy controls.